Biogen (BIIB) Aktsia Kursus
Biogen Kursus
Käive kasvas 7,1 % aastas viimase 19 aasta jooksul 9,89 B USD-ni. Kasum aktsia kohta kasvas 14,9 % aastas viimase 19 aasta jooksul. Biogen netomarginaal on nüüd 13,1 %, langenud 14,2 %-lt mõni aasta tagasi. Analüütikute hinnasihi mediaan on 240,00 USD, st alla praegust hinda 5,0 %. 43 analüütikust 29 soovitab osta — üldine konsensus on Osta.
Biogen aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Biogen ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Biogen aktsia kohta
Biogen Inc.'s business model revolves around the development, manufacturing, and commercialization of therapies for neurological, autoimmune, and rare diseases. As a leading biotechnology company, Biogen focuses on creating innovative treatments to address unmet medical needs. With a diverse portfolio encompassing multiple therapeutic areas, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, Biogen strives to improve patients' lives worldwide. Through strategic collaborations and scientific advancements, the company continues to invest in cutting-edge research and development to bring transformative therapies to patients, making Biogen a key player in the biopharmaceutical industry.
Biogen Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Biogen Inc in the market are Amgen Inc, AbbVie Inc, and Gilead Sciences Inc.
Biogen Inc is a renowned biotechnology company with a rich history and impressive background. Founded in 1978, Biogen has consistently aimed to develop innovative therapies for patients facing serious neurological and neurodegenerative diseases. Over the years, the company has made significant contributions to the field of biotechnology, especially in areas like multiple sclerosis (MS) and spinal muscular atrophy (SMA). Biogen's mission involves relentless pursuit of scientific excellence and commitment to improving patients' lives. With a diverse portfolio of groundbreaking therapies and a global presence, Biogen continues to be a leading player in the biotechnology industry, dedicated to transforming the course of human health.
Biogen Inc, a leading biotechnology company, has achieved several significant milestones. Notably, the company successfully introduced the first treatment for multiple sclerosis, revolutionizing the lives of patients worldwide. Biogen also developed ground-breaking therapies for spinal muscular atrophy, empowering patients with this rare genetic disease. Moreover, the company made strides in neurology and introduced medications addressing Alzheimer's disease and Parkinson's disease. Biogen's commitment to innovation has led to these remarkable achievements, positioning the company as a pioneer in the biotech industry. As an influential player, Biogen Inc continues to drive advancements in healthcare, improving the quality of life for countless individuals.
Biogen Inc operates in several countries and regions around the world. As a leading biotechnology company, Biogen Inc has a significant presence in the United States, where it is headquartered. Additionally, Biogen Inc has operations and presence in Europe, including countries such as Germany, France, Italy, and Switzerland. The company also serves markets in Asia, with a presence in Japan, South Korea, and several other countries in the region. Biogen Inc's global footprint allows it to reach a wide range of patients and healthcare providers, ensuring its innovative therapies and treatments are accessible to individuals in various parts of the world.
Biogen Inc is a biotechnology company known for its commitment to scientific innovation and improving patients' lives. Guided by their corporate philosophy, Biogen Inc strives to discover, develop, and deliver innovative therapies for neurological, autoimmune, and rare diseases. The company values integrity, diversity, and inclusion in their pursuit of breakthrough treatments, always putting patients at the forefront. Biogen Inc's collaborative approach, dedication to scientific rigor, and passion for making a difference have earned it a leading position in the biotech industry. With a focus on transformative therapies, Biogen Inc continues to drive advancements in healthcare and empower patients worldwide.
Analüütikud määravad Biogen aktsiale keskmiseks hinnasihi 238,69 USD (mediaan: 240,00 USD), mis on −5,6 % viimase hinna suhtes. Konsensus põhineb 43 analüütiku hinnangul.
43 analüütikut hindavad praegu Biogen aktsiat: 29 soovitab osta, 13 hoida ja 1 müüa. 2026. aastaks ootavad analüütikud, et Biogen teenib tulu 10,46 B USD ja kasumit aktsia kohta 12,35 USD.
Praeguse kursiga kaubeldakse Biogen aktsiaga 226,81 EUR (252,73 USD) juures.
Biogen aktsia (BIIB) on noteeritud 11 börsil, sh: NASDAQ (BIIB), London (0R1B.L), SIX (Zürich) (BIIB.SW), XETRA (IDP.DE), Frankfurt (IDP.F), München (IDP.MU), Düsseldorf (IDP.DU), Hamburg (IDP.HM).
Biogen Inc. is a biopharmaceutical company specializing in the research, development, and marketing of therapies for neurological, hematological, and autoimmune diseases. It was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen currently has three main business segments: Neurology, Hematology, and Biosimilars. The Neurology division focuses on the development and marketing of drugs for the treatment of Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and other neurological disorders. The Hematology division focuses on the development of therapies for blood diseases such as Hemophilia and Sickle Cell Anemia. The Biosimilars division focuses on the development of generic versions of biological drugs. Biogen has partnerships with other major companies such as Eisai Co. and Ionis Pharmaceuticals to work on the development of new drugs and therapies. The company's business model is based on the sale of patented drugs and the development of new therapies. In summary, Biogen is a biopharmaceutical company specializing in the development and marketing of therapies for neurological, hematological, and autoimmune diseases, aiming to improve the lives of patients worldwide.
oodatav Biogen käive on 10,46 B USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Biogen kasum on 1,82 B USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Biogen jaoks on praegu 20,46. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Biogen aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Biogen jaoks on praegu 3,55. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Biogen aktsia jaoks.
Eulpooli kvaliteedinäitaja Biogen jaoks on 3/10.
Biogen ISIN on US09062X1037. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Biogen WKN on 789617. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Biogen ticker on BIIB. Ticker-sümbol kasutatakse Biogen aktsiate kauplemiseks börsil.
Biogen aktsia
Biogen Börsiticker
Biogen FIGI
Kõik teised näitajad ja analüüsid Biogen kohta sügavamalt
Meie Biogen-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Biogen. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: